CA2797458A1 - Tablet formulation of ezatiostat - Google Patents

Tablet formulation of ezatiostat Download PDF

Info

Publication number
CA2797458A1
CA2797458A1 CA2797458A CA2797458A CA2797458A1 CA 2797458 A1 CA2797458 A1 CA 2797458A1 CA 2797458 A CA2797458 A CA 2797458A CA 2797458 A CA2797458 A CA 2797458A CA 2797458 A1 CA2797458 A1 CA 2797458A1
Authority
CA
Canada
Prior art keywords
tablet
pharmaceutically acceptable
percent
weight
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2797458A
Other languages
English (en)
French (fr)
Inventor
Robert T. Lum
Stephan D. Parent
Chunsheng Qiao
Steven R. Schow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telik Inc
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Publication of CA2797458A1 publication Critical patent/CA2797458A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2797458A 2010-06-07 2011-03-29 Tablet formulation of ezatiostat Abandoned CA2797458A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35237710P 2010-06-07 2010-06-07
US61/352,377 2010-06-07
PCT/US2011/030376 WO2011156045A2 (en) 2010-06-07 2011-03-29 Tablet formulation of ezatiostat

Publications (1)

Publication Number Publication Date
CA2797458A1 true CA2797458A1 (en) 2011-12-15

Family

ID=42829329

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2797458A Abandoned CA2797458A1 (en) 2010-06-07 2011-03-29 Tablet formulation of ezatiostat

Country Status (8)

Country Link
US (2) US20110300215A1 (https=)
EP (1) EP2576591A2 (https=)
JP (1) JP2013528213A (https=)
CN (1) CN102917694A (https=)
AR (1) AR080895A1 (https=)
CA (1) CA2797458A1 (https=)
TW (1) TW201143761A (https=)
WO (1) WO2011156045A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2831340A1 (en) * 2011-05-03 2012-11-08 Robert T. Lum Excipient compatibility with ezatiostat
US20130035389A1 (en) 2011-08-05 2013-02-07 Telik, Inc. Methods for treating myelodysplastic syndrome with ezatiostat
US10156885B2 (en) 2014-04-07 2018-12-18 Avago Technologies International Sales Pte. Limited Network energy consumption reduction
WO2016117927A1 (ko) 2015-01-20 2016-07-28 주식회사 한림포스텍 무선 전력 전송 장치 및 이의 전송 전력 제어 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599903A (en) 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
US5114003A (en) * 1991-03-28 1992-05-19 E. I. Du Pont De Nemours And Company Tablet vial with desiccant in bottom
US5786336A (en) 1991-04-29 1998-07-28 Terrapin Technologies, Inc. Target-selective protocols based on mimics
US5955432A (en) * 1992-04-03 1999-09-21 Terrapin Technologies, Inc. Metabolic effects of certain glutathione analogs
US5965164A (en) 1994-10-28 1999-10-12 Fuisz Technologies Ltd. Recipient-dosage delivery system
ATE297945T1 (de) * 1998-04-16 2005-07-15 Teijin Ltd Glutathionderivate und dazugehörige dosisformen
CA2445290A1 (en) * 2001-04-26 2002-11-07 Chenkou Wei A pharmaceutical tablet having a high api content
US7029695B2 (en) 2001-07-10 2006-04-18 Telik, Inc. Therapeutic compositions containing glutathione analogs
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2005065639A2 (en) 2003-11-21 2005-07-21 Torrent Pharmaceuticals Limited Novel pharmaceutical compositions
CN101133020A (zh) * 2004-12-03 2008-02-27 特瓦制药工业有限公司 依泽替米贝多晶型
EP1833978B1 (en) * 2005-01-06 2008-10-08 Telik, Inc. Tripeptide and tetrapeptide thioethers
ATE460934T1 (de) 2006-07-19 2010-04-15 Tabuk Pharmaceutical Mfg Co Pharmazeutische zubereitungen von ciprofloxacin
EA017349B1 (ru) * 2007-01-24 2012-11-30 Крка Способ получения эзетимиба и его производных
WO2008090569A1 (en) 2007-01-25 2008-07-31 Panacea Biotec Ltd Modified release pharmaceutical composition and a process of making the same
MX2010001711A (es) 2007-08-13 2010-03-11 Panacea Biotec Ltd Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.
AR068745A1 (es) 2007-10-08 2009-12-02 Panacea Biotec Ltd Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos

Also Published As

Publication number Publication date
WO2011156045A3 (en) 2012-05-31
JP2013528213A (ja) 2013-07-08
US20120021054A1 (en) 2012-01-26
CN102917694A (zh) 2013-02-06
WO2011156045A2 (en) 2011-12-15
EP2576591A2 (en) 2013-04-10
TW201143761A (en) 2011-12-16
AR080895A1 (es) 2012-05-16
US20110300215A1 (en) 2011-12-08
US8361971B2 (en) 2013-01-29

Similar Documents

Publication Publication Date Title
FI2508188T3 (fi) Dapagliflotsiinipropyleeniglykolihydraattia sisältäviä farmaseuttisia formulaatioita
JP2011098964A5 (https=)
JP2008501025A5 (https=)
HRP20240564T1 (hr) Novi farmaceutski sastav
UA116334C2 (uk) Тверді форми дозування бендамустину
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
MY153608A (en) Use of dronedarone for the preparation of medicament for use in the prevention of cardiovascular hospitalization or of mortality
NZ729172A (en) Combination formulation of two antiviral compounds
JP2010527347A5 (https=)
NZ604055A (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
WO2009081174A3 (en) Anti - retroviral combination
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
NZ711179A (en) Oral formulations of deferasirox
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
WO2011053003A3 (en) Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer
WO2009034431A3 (en) Controlled-release dosage forms for varenicline
MY157307A (en) Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbersartan
CA2797458A1 (en) Tablet formulation of ezatiostat
MX2010007281A (es) Composiciones farmaceuticas de amlodipina y valsartan.
WO2011141791A3 (en) Extended release formulations of desvenlafaxine base
JP2013528213A5 (https=)
EP2497464A3 (en) Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture
FI3263096T3 (fi) Rivaroksabaanin farmaseuttinen kapselikoostumus
WO2012010944A3 (en) Multiple unit tablet composition

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160330